Articles with "neoantigen specific" as a keyword



Photo by nci from unsplash

Harnessing neoantigen specific CD4 T cells for cancer immunotherapy

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Leukocyte Biology"

DOI: 10.1002/jlb.5ri0220-603rr

Abstract: The goal of precision immunotherapy is to direct a patient's T cell response against the immunogenic mutations expressed on their tumors. Most immunotherapy approaches to‐date have focused on MHC class I‐restricted peptide epitopes by which… read more here.

Keywords: cd4 cells; immunotherapy; cells cancer; cancer immunotherapy ... See more keywords
Photo from wikipedia

In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.

Sign Up to like & get
recommendations!
Published in 2020 at "Cytotherapy"

DOI: 10.1016/j.jcyt.2020.10.003

Abstract: Therapies that utilize immune checkpoint inhibition work by leveraging mutation-derived neoantigens and have shown greater clinical efficacy in tumors with higher mutational burden. Whether tumors with a low mutational burden are susceptible to neoantigen-targeted therapy… read more here.

Keywords: neoantigen specific; low mutational; specific cells; burden ... See more keywords
Photo by nci from unsplash

The mutant neoantigen specific T cell is a personalized immunotherapy in refractory solid tumour

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz253.054

Abstract: Abstract Background Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is… read more here.

Keywords: neoantigen; neoantigen specific; cell personalized; personalized immunotherapy ... See more keywords
Photo from wikipedia

Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection

Sign Up to like & get
recommendations!
Published in 2022 at "Science Translational Medicine"

DOI: 10.1126/scitranslmed.abo7604

Abstract: Upon chronic antigen exposure, CD8+ T cells become exhausted, acquiring a dysfunctional state correlated with the inability to control infection or tumor progression. In contrast, stem-like CD8+ T progenitors maintain the ability to promote and… read more here.

Keywords: cell; tumor; neoantigen specific; cd8 cells ... See more keywords
Photo from wikipedia

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma

Sign Up to like & get
recommendations!
Published in 2022 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2022-005328

Abstract: Background Merkel cell carcinoma (MCC) often responds to PD-1 pathway blockade, regardless of tumor-viral status (~80% of cases driven by the Merkel cell polyomavirus (MCPyV)). Prior studies have characterized tumor-specific T cell responses to MCPyV,… read more here.

Keywords: cell; response; cd4 cells; neoantigen specific ... See more keywords
Photo by nci from unsplash

Abstract 4055: Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung cancer patients responding to atezolizumab treatment

Sign Up to like & get
recommendations!
Published in 2019 at "Immunology"

DOI: 10.1158/1538-7445.am2019-4055

Abstract: There is strong evidence that immunotherapy-mediated tumor rejection can be driven by the reinvigoration of tumor-specific CD8+ T cells recognizing neoantigens derived from tumor somatic mutations (citations). Thus, it is possible that the relative abundance… read more here.

Keywords: specific cd8; cd8 cells; cd8; specific cells ... See more keywords
Photo from wikipedia

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Sign Up to like & get
recommendations!
Published in 2019 at "Genome Medicine"

DOI: 10.1186/s13073-019-0697-8

Abstract: BackgroundThe efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of… read more here.

Keywords: neoantigen; mutation burden; neoantigen specific; colorectal cancers ... See more keywords